Regulatory Approval
Regulatory approval in M&A refers to governmental clearances, consents, waiting-period expirations or other regulatory actions required before a transaction may lawfully close under applicable antitrust, foreign-investment, industry-licensing or other laws.
Approval can be a legal prerequisite to closing
For reportable U.S. transactions, HSR rules require advance notification and a waiting period before consummation. Other jurisdictions can impose their own merger-control or foreign-investment regimes.
Industry-specific licenses can create additional change-of-control approvals.
Not every transaction requires the same filings
HSR thresholds are updated periodically, and exemptions can apply. Cross-border requirements depend on local turnover, assets, transaction value or other jurisdictional tests.
A transaction team therefore builds a jurisdiction-specific regulatory map rather than assuming one universal approval process.
Second Requests and extended review can delay closing
The FTC or DOJ can investigate a proposed transaction more deeply. In 2026, DOJ announced a return to targeted Second Request investigations intended to focus merger review while preserving enforcement authority.
A lengthy review can consume much of the period before the contractual Outside Date.
Clearance risk is allocated by contract
The merger agreement usually specifies the efforts each party must use to obtain approval. The buyer may agree to divest assets, accept operating restrictions or litigate against a regulator—or may expressly refuse to accept burdens beyond a negotiated threshold.
That allocation can be as economically important as the regulatory filing itself.
Regulatory approval is a timeline risk as well as a legal risk
Even when the parties expect eventual clearance, the time required to obtain it can affect financing costs, employee retention, customer behavior and the seller’s ability to operate under interim covenants.
A prolonged review can also push the transaction toward its Outside Date. That is why merger agreements often coordinate regulatory-efforts obligations, extension rights and termination fees rather than treating clearance as a standalone legal checklist item.
For large transactions, the economic cost of delay can be meaningful even when the deal ultimately closes.
Approval and remedy are different stages
A regulator can allow a transaction to proceed without conditions, challenge it, or accept a remedy that changes the deal's economics. The parties therefore need to distinguish obtaining legal clearance from obtaining clearance on acceptable terms.
That is where the regulatory covenant becomes critical. The buyer may be required to accept certain remedies but not others, and the seller's ability to terminate or collect a reverse fee can depend on whether the buyer satisfied those obligations.
Common mistakes
Treating HSR filing as approval Filing starts a review process; it does not itself authorize closing.
Assuming federal U.S. clearance is the only issue Foreign and industry-specific approvals can matter.
Ignoring contractual risk allocation The regulatory covenant determines what the buyer must do to obtain clearance.
Example
A merger requires HSR clearance in the United States plus foreign antitrust and investment approvals in several jurisdictions. Even if stockholders approve the deal and financing is ready, the parties cannot close while a required legal restraint or waiting period remains outstanding.
Example
A merger requires HSR clearance in the United States plus foreign antitrust and investment approvals in several jurisdictions. Even if stockholders approve the deal and financing is ready, the parties cannot close while a required legal restraint or waiting period remains outstanding.
Professional note
Regulatory approval should be analyzed together with the buyer’s efforts covenant, divestiture obligations, outside date and reverse termination fee. Those terms determine who bears the economic risk of delayed or denied clearance.
Related terms
- Material Adverse Effect (MAE)
A Material Adverse Effect, or MAE, is a contractually defined level of adverse change that can affect specified rights or closing conditions in an acquisition agreement. The definition typically includes broad adverse-effect language followed by negotiated exclusions and, often, disproportionate-impact exceptions.
- Reverse Termination Fee
A reverse termination fee is a contractual payment that a buyer or parent may owe the seller or target if an acquisition agreement is terminated under specified circumstances defined in the agreement.
- Closing Condition
A closing condition is a requirement specified in an acquisition agreement that must be satisfied or, when legally permitted, waived before a party becomes obligated to complete the transaction.
Related ROIStreet guides
- What Is the Rule of 55?
The Rule of 55 is an informal name for a federal exception to the 10% additional tax on certain early retirement-plan distributions. It can apply when a worker separates from the employer maintaining a qualified plan in or after the calendar year the worker reaches age 55. This guide explains the age test, eligible plans, IRA differences, taxes, rollovers and special public-safety rules.
- Stocks vs. Bonds: A Practical Comparison
Stocks represent ownership in companies; bonds generally represent lending to an issuer. This comparison explains how the two differ in return sources, volatility, income, maturity, priority, credit risk and liquidity.
- What Is a 401(k) Recordkeeper?
A 401(k) recordkeeper maintains the participant-level ledger: contributions, investments, gains and losses, fees, loans, distributions and account balances. The recordkeeping role is distinct from holding plan assets, writing the plan document or serving as the legal plan administrator, even when one financial company bundles several of those services.
- What Compensation Counts for a 401(k)?
There is no single universal 401(k) compensation number. A plan can use different definitions for deferrals, matching, profit sharing and testing, while statutory definitions govern limits such as Sections 401(a)(17), 414(s) and 415.